alain R THIERRY | Data Science and Deep Learning | Excellence in Research

Posted on by ScienceFather

Prof. alain R THIERRY  | Data Science and Deep Learning | Excellence in Research

Director of Research, INSERM U1194, France

Dr. alain R THIERRY, a distinguished biologist, and cancer researcher, is a Director of Research at INSERM and a key figure at the Institut de Recherche en Cancérologie de Montpellier. With an impressive track record in molecular biology, gene therapy, and cancer research, Dr. alain R THIERRY has held numerous influential positions in academia and the biotechnology sector, including roles at NIH and Georgetown University. A prolific author and scientific leader, they have also founded biotech companies like MedinCell and DiaDx. Dr. alain R THIERRYcontinues to drive innovative therapeutic solutions, recognized by international honors and awards.

Publication Profile

scholar

Education🎓 

2003: Habilitation à Diriger les Recherches (HDR) in Biology-Health, Université Montpellier II 1987: CES in Human Biology (Oncology), Faculté de Médecine Paris-Sud 1986: PhD in Biochemistry, Cellular & Molecular Pharmacology, Université Montpellier II 1983: MSc in Cellular & Molecular Biology, Université de Clermont-Ferrand II 1983: Diplôme d’Ingénieur, Université Clermont-Fd II 1982: BSc in Biological Sciences & Technology, Université Clermont-Fd

Professional Experience💼 

208-present: Director of Research, INSERM, Institut de Recherche en Cancérologie, Montpellier 2001-2007: Associate Professor, Université Montpellier II2003-2004: Director of R&D, MedinCell SA, Montpellier 1997-2000: Scientific Director, Gene Therapy Dept., Biovector Therapeutics 1992-1996: Scientist, Tumor Cell Biology Lab, NCI/NIH, Bethesda 1992-1994: Adjunct Assistant Professor, Lombardi Cancer Institute, Washington DC 1988-1992: Postdoctoral Fellow, Lombardi Cancer Center, Georgetown University

Awards and Honors🏆 

1994: Federal Technology Award, NIH, USA ($10,000) 2002: Prix National de l’Innovation, Ministry of Education and Research, Paris (€300,000) 2016: Grand Prix de l’Innovation Thérapeutique, Fondation B. Denys & FRM, Montpellier (€50,000) 2022: Finalist, Prix Innovation Unicancer 2022: Innovation Award, Montpellier Université Excellence

Research Focus 🔬 

Molecular Oncology: Pioneer in understanding the molecular pathways of cancer and therapeutic gene delivery Gene Therapy: Focus on targeted gene therapy to treat cancers, with expertise in vectors and delivery systems Circulating DNA: Breakthrough research in non-invasive biomarkers for early cancer detection
Therapeutics Innovation: Key developer of novel therapeutic strategies, including drug delivery systems and cancer diagnostics
Collaborative Research: Strong interdisciplinary collaborations in biotechnology and cancer research

Publication  Top Notes

  • Origins, structures, and functions of circulating DNA in oncology
    AR Thierry, S El Messaoudi, PB Gahan, P Anker, M Stroun
    Cancer and Metastasis Reviews, 2016 | 812 citations
  • Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
    AR Thierry, F Mouliere, S El Messaoudi, C Mollevi, E Lopez-Crapez
    Nature Medicine, 2014 | 735 citations
  • Nomenclature for synthetic gene delivery systems
    PL Felgner, Y Barenholz, JP Behr, SH Cheng, P Cullis, L Huang, AR Thierry
    Human Gene Therapy, 1997 | 652 citations
  • High fragmentation characterizes tumour-derived circulating DNA
    F Mouliere, B Robert, E Arnau Peyrotte, M Del Rio, M Ychou, F Molina, AR Thierry
    PLOS One, 2011 | 627 citations
  • Circulating cell-free DNA: preanalytical considerations
    S El Messaoudi, F Rolet, F Mouliere, AR Thierry
    Clinica Chimica Acta, 2013 | 602 citations

Conclusion:

This individual is highly suitable for the Best Researcher Award. Their long-standing career in oncology research, leadership in both academic and biotech sectors, and recognition through awards place them in an elite category of researchers. Continued engagement in broader interdisciplinary fields and public communication could further elevate their profile. Overall, their qualifications, contributions, and leadership make them a strong candidate for excellence in research awards.